Canntab Therapeutics Limited, an innovator in cannabinoid and terpene blends in hard pill form for medical and therapeutic applications, has completed its first delivery of two (2) of a total of five (5) SKU’s ordered by MediPharm Labs Corp. Further to Canntab’s press release dated June 2, 2020, the Company confirms that the total purchase order is approximately $1.3 Million. Canntab intends to complete and deliver the entire order by the end of 2020.
“Our first commercial production and delivery of this initial portion of our order from MediPharm Labs Corp. is a major milestone event for our company for three important reasons. First, this is evidence our science, quality assurance programs and production can be executed with the required standards to reflect our unique patented product of pressed tablets and caplets. Second, Canntab’s wide range of products will finally be available to all Canadians through a variety of retail and wholesale channels,” explains Larry Latowsky, Chief Executive Officer of Canntab.
“Finally, Canntab will be able to recognize revenue from its core product that will have a strong distribution base which will result in continuous sales through further expansion. Canntab will continue to enhance shareholder value by growing revenue through its domestic channels and expanding sales to international customers.”
Canntab Therapeutics is a Canadian biopharmaceutical company focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations. Canntab’s proprietary hard pill cannabinoid formulations provide doctors, patients and consumers with medical grade solutions which incorporate all the features one would expect from any prescription or over the counter medication sold in Canadian pharmacies. These will include the following formulations: once a day and extended release, both providing an accurate dose and improved shelf stability.